Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...
First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...
MedPage Today on MSN
'Amazing' Results With Drug Combo in Metastatic Cervical Cancer
Combination with investigational antibody-drug conjugate showed encouraging antitumor acti ...
The Phase II cohort analysis included 145 patients whose conditions had progressed following initial chemotherapy.
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
SCLC, addressing a high-relapse setting with limited second-line efficacy and modest survival benefit. Ifinatamab deruxtecan ...
Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.
Recurrent/metastatic EC has a poor long-term prognosis, and treatment options are limited beyond first line, said Pothuri.
A new national cohort study provides important insights into the treatment of multidrug-resistant tuberculosis (MDR-TB). The ...
Speaking to Fierce at the European Society for Medical Oncology (ESMO) Congress in Berlin at the time, GSK’s Hesham Abdullah, ...
The fight for two tumor types is poised to intensify, with BioNTech lining up a challenge to AstraZeneca, while SynOx Therapeutics is planning to enter a market served by companie ...
GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers: London, UK Tuesday, April 14, 2026, 13:00 Hrs [IST] GSK plc announced positive findings from its globa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results